Proteinuria Severity in Lupus Nephritis is Associated with Anti-dsDNA Level and Immune Complex Deposit Location in Kidney by Engli, K. (Katherina) et al.
JOURNAL OF TROPICAL LIFE SCIENCE 
2018, Vol. 8, No. 3, 217 - 226 
http://dx.doi.org/10.11594/jtls.08.03.03 
 
 
 
How to cite: 
Engli KA, Handono K, Eko MH et al. (2018) Proteinuria Severity in Lupus Nephritis is Associated with Anti-dsDNA Level 
and Immune Complex Deposit Location in Kidney. Journal of Tropical Life Science 8 (3): 217 – 226. doi: 
10.11594/jtls.08.03.03 
Research Article  
 
 
Proteinuria Severity in Lupus Nephritis is Associated with Anti-dsDNA Level and 
Immune Complex Deposit Location in Kidney  
 
Katherina Alfa Engli 1, 2 *, Kusworini Handono 1, 2, Mudjiwijono Handaru Eko 2, 3, Hani Susianti 1, 2, 
Atma Gunawan 2, 4, Handono Kalim 2, 4 
 
1 Department of Clinical Pathology, Faculty of Medicine, Brawijaya University, Malang 65145, Indonesia 
2 dr. Saiful Anwar Public Hospital, Malang 65112, Indonesia 
3 Department of Anatomical Pathology, Faculty of Medicine, Brawijaya University, Malang 65145, Indonesia 
4 Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang 65145, Indonesia 
 
 
Article history: 
Submission March 2018 
Revised May 2018 
Accepted July 2018 
 
 
ABSTRACT 
 
Lupus nephritis (LN) is one of the manifestations of Systemic Lupus Erythematosus 
(SLE), with proteinuria being one of the clinical manifestations. The proteinuria path-
ogenesis is associated with anti-dsDNA antibody and the location of immune complex 
deposits within the kidney. This study aims to investigate the correlation of the sever-
ity of proteinuria with the location of immune complex deposits and the level of anti-
dsDNA antibody in LN. Data were collected in cross-section. Fifty-three patients with 
LN in Saiful Anwar Hospital Malang, who underwent renal biopsy, were included. 
Hematoxylin-eosin staining and immunofluorescence analysis were used to assign 
subjects to different histopathological classes and determine the immune complex de-
posits. The spot urine samples were evaluated using the dipstick method for semi-
quantitative proteinuria. The anti-dsDNA antibody levels were evaluated using the 
enzyme-linked immunosorbent assay (ELISA). Turbidity and enzymatic tests were 
conducted to elucidate urine protein and creatinine content, respectively. The level of 
proteinuria is significantly different among the different locations of immune complex 
based on the dipstick and protein/creatinine methods (p = 0.021 and p = 0.005, respec-
tively). There was a significant correlation between anti-dsDNA antibody level and 
the severity of proteinuria (r = 0.326 based on dipstick and r = 0.28 based on pro-
tein/creatinine method). Thus, proteinuria in LN is determined by anti-dsDNA level 
and the location of immune complex deposits in the kidney. 
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Introduction 
Systemic Lupus Erythematosus (SLE) is an 
autoimmune disease involving many organ sys-
tems, including the kidney, skin, lung, heart, 
blood, and brain, characterized by autoantibody 
and immune complex deposition causing tissue 
damage [1, 2]. SLE can affect all age groups, but 
mostly affects people of reproductive age, be-
tween 15 and 40 years old [3]. The annual inci-
dence of SLE in America is 5.1 per 100,000, while 
the prevalence of SLE is 52 cases per 100,000 
populations [4]. The frequency is higher in fe-
males compared to males, with the ratio of 9 – 14 
: 1. There are no epidemiological data of SLE 
which include all areas of Indonesia. Data from 
RSUP Cipto Mangunkusumo (RSCM) Jakarta in 
2012 showed that 1.4% of all patient visits in the 
Rheumatology Polyclinic of the Internal Medicine 
Department was SLE cases, while there were 291 
SLE patients or approximately 10.5% of all pa-
tients visiting the Rheumatology Polyclinic in Ha-
san Sadikin Bandung Hospital during 2010 [5]. 
SLE has many clinical manifestations; one of 
the most serious manifestations, involving the kid-
ney, is known as lupus nephritis (LN). Patients 
with SLE show abnormal urinalysis results or re- 
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nal dysfunction of about 25 – 50% in the begin-
ning of the disease. This can increase to 60% in 
adult patients, developing into chronic kidney dis-
ease and end-stage renal disease (ESRD) in at least 
5 years [6]. The United States Renal Data Service 
noted that the incidence of ESRD caused by LN in 
1996–2004 was 4.5 cases per 1 million popula-
tions [7]. LN is more commonly found in people 
of Asian and African ethnicity; these groups also 
have a worse prognosis compared to other races 
[6]. The frequency of LN in Malang is relatively 
high. A study by Handono of 31 SLE patients who 
underwent renal biopsy showed that 58% of pa-
tients had LN with a poor prognosis, LN class III, 
IV, and V, which mostly end in renal failure. The 
study mentioned that 37.5% of the 8 patients with 
normal laboratory results had a histopathological 
classification of LN class III and IV [8]. 
The presentation of renal disorder in LN can 
be divided into nephritic and nephrotic presenta-
tions based on clinical manifestations and labora-
tory studies. The difference in pathological pro-
cesses of both presentations is not clearly under-
stood. The clinical manifestation of this disorder 
is related to the immune complex deposits located 
in the kidney and the type of immunoglobulin (Ig) 
involved, presumably as the trigger of inflamma-
tion [9]. 
The recent opinion states that the location of 
immune complex deposits is one of the causes of 
the differences in the nephritic and nephrotic man-
ifestations of LN. Immune complex deposits in 
subendothelial and mesangial regions will show a 
nephritic appearance. Histopathologically, it 
shows a mesangial, focal and diffuses proliferative 
appearance, and clinically shows active urine sed-
iment (erythrocyte, leukocyte, cylinder cell, and 
granules), mild proteinuria, and normal or slightly 
reduced renal function [10,11]. Immune complex 
deposits in the subepithelial region histopatholog-
ically show membranous nephropathy appearance 
and clinically induce symptoms of severe pro-
teinuria [9, 11]. This is probably because the sub-
epithelial area does not relate to the blood vessels 
because it is separated by the basal membrane of 
the glomerulus [9]. Some cases have been reported 
with immune complex deposits in the mesangial 
region, which showed a nephrotic instead of a ne-
phritic appearance [10]. A study by Han et al. also 
showed that the location of immune complex de-
posits had no relationship with the proteinuria in  
LN [12]. 
The main immunological disorder in SLE is 
the autoreactive T and B cells producing many 
types of autoantibody [13, 14]. One of the specific 
antibodies for SLE is the double-stranded deoxy-
ribonucleic acid (anti-dsDNA) antibody, espe-
cially the IgG class, which is believed to play an 
important role in the pathogenesis of organ mani-
festations, especially glomerulonephritis [13, 15], 
it can also be found along with IgM and IgA [9, 
16]. The autoimmune response of the dsDNA an-
tibody is considered as the main mediator of the 
inflammatory response that leads to kidney dam-
age [14, 17]. Some studies show that anti-dsDNA 
antibodies and complement are useful in assessing 
the disease and renal activity [14, 18].  
Generally, the assessment of renal activity in 
LN is based on the clinical variables of active 
urine sediment, amount of proteinuria, and a de-
crease in renal function [18, 19]. Some studies 
suggest the significance of proteinuria in kidney 
damage pathogenesis [20]. Waldman and Madaio 
also Villalta et al. stated that there was an associa-
tion between the titer of anti-dsDNA antibody and 
disease activity, and the anti-DNA antibody was 
found in immune deposits in the glomerulus of hu-
mans and rats with nephritis [14, 15]. Moroni et al. 
found that LN patients with high anti-dsDNA lev-
els had significantly higher proteinuria compared 
to normal subjects [18]. As the matter of fact, the 
anti-dsDNA antibody and proteinuria severity can 
serve as diagnostic markers and help in assessing 
treatment’s effectiveness [15, 21]. 
The arguments above illustrate the signifi-
cance of the proteinuria and anti-dsDNA antibod-
ies in the pathogenesis of kidney damage, but the 
association among these two markers in LN is not 
well understood yet. Therefore, this study tried to 
elucidate the association by comparing the anti-
body’s quantity and deposit locations to pro-
teinuria severity in LN patients. This study took 
urine and serum samples from patients who had 
undergone renal biopsy and examined the IgG of 
anti-dsDNA antibodies, as well as the histopathol-
ogy of the immune complex deposits located in the 
kidney to understand the association with pro-
teinuria severity. 
 
Material and Methods 
Research design and ethical consideration 
This was an observational, cross-sectional stu- 
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dy. The population studied was composed of SLE 
patients visiting the internal medicine polyclinic 
or inpatient division of the Department of Internal 
Medicine in Saiful Anwar Public Hospital, Ma-
lang. The study samples were SLE patients diag-
nosed with LN by rheumatology consultants based 
on the ARA 1997 criteria and the results of renal 
biopsy histopathology. The data in this study were 
taken between July 2012 and June 2014. This 
study was approved by the ethical committee of 
Faculty of Medicine, Brawijaya University and 
Saiful Anwar Public Hospital, Malang with ap-
proval number No.469/EC/KEPK/08/2014. The 
inclusion criteria of this study were patients diag-
nosed with LN, tissue samples from renal biopsy 
with more than 10 glomeruli, and the patient 
agrees to participate in this study, including sign-
ing the informed consent. The exclusion criteria 
were patients with the congenital renal disorder, 
frank infection (leukocyturia) during sampling, 
and diabetes mellitus. Sample size calculation was 
based on Dahlan’s formulation in correlational ob-
servational study [22], detailed as follow: 
 
𝑛 =  (
𝑍𝛼 + 𝑍𝛽
0.5 𝐿𝑛((1 + 𝑟)/(1 − 𝑟))
)
2
+ 3 
 
Note: 
n : Minimum sample size 
Zα : Normal distribution value (Z table) in α value 
Zβ : Normal distribution value (Z table) in β value 
r : Correlation value 
 
for Zα (5%) = 1.645; Zβ (10%) = 1.282; and r = 
0.394, the minimum sample size would be: 
 
  𝑛 =  (
1.645+1.282
0.5 𝐿𝑛((1+0.394)/(1−0.394))
)
2
+ 3 = 52.38 
 
or rounded to 53 subjects in order to represent the 
population. 
 
Tissue sampling and preservation 
The renal biopsy was performed by a Renal 
and Hypertension Consultant Internist in the De-
partment of Renal and Hypertension, Department 
of Internal Medicine, Saiful Anwar Public Hos-
pital, Malang guided by ultrasonography (USG). 
Tissue sampling was undertaken twice. The tissue 
sample had to have at least 10 glomeruli. The first 
tissue sample was preserved in formalin 10%, 
while the second was preserved using Optimum 
Cutting Temperature (OCT) compound. The renal 
tissue was sent to Laboratory of Anatomical Pa-
thology immediately for embedding and paraffi-
nization. Tissue cutting was performed with the 
thickness of 3.5 μm. The preparation was fixed on 
object glass and stained using immunofluores-
cence staining. 
 
Preparation and immunofluorescence staining 
The immune complex deposit location was the 
region in the glomerulus which had immune 
complex deposits stained with rabbit anti-human 
IgG/FITC polyclonal antibodies. Immunofluores-
cence staining was performed according to Ban-
croft and Gamble modifications, which state that 
the preparation was incubated at 37°C in an oven 
overnight. The preparation was then placed on a 
hot plate for 3 hours to maximize tissue adhesion 
to the object glass. Deparaffinization was perform-
ed using xylol I and II, each for 5 minutes. Sam-
ples were then dehydrated using absolute alcohol 
for 5 minutes, twice. After that, the preparation 
was dehydrated using 90% and 70% alcohol for 5 
minutes each, and then soaked in 1 M phosphate 
buffer saline (PBS) pH 7.4 3 times, for 5 minutes 
each, before it was soaked in 10 mM citrate buffer 
pH 6 and heated in a high-temperature microwave 
for ± 8 minute. The preparation was taken from the 
microwave, placed at room temperature, and then 
soaked 3 times for 5 minutes each. The preparation 
was dried of PBS residue and placed in a container 
layered with tissue paper and sprayed with water. 
Blotto solution (skim milk 2%) was dropped onto 
the tissue and kept for 1 hour at room temperature. 
The preparation was then washed using PBS for 3 
times, for 10 minutes each. PBS residue was dried 
and the antibody was prepared. Rabbit anti-human 
IgG/FITC polyclonal antibody (Fluorescein Iso-
thiocyanate Isomer 1) (DAKO®) was dissolved in 
skim milk with a ratio of 1 : 1000. The primary 
antibody solution was dropped onto the prepara-
tion and then incubated for 1 hour at room tempe-
rature. The preparation was washed with PBS 3 
times, for 10 minutes each, and then the PBS resi-
due was dried [23]. After that, the preparation was 
observed using an immunofluorescence micros-
cope (FSX 100 Olympus®), at a magnification of 
400x. The location of immune complex deposits 
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was evaluated by an anatomical pathology spe-
cialist. 
 
Anti-dsDNA assay 
The anti-dsDNA level was the level of anti-
body shown in the DNA. Anti-dsDNA antibody 
examination was performed using ELISA method 
(Cat#2553Z, Diagnostic automation, Inc®, Cala-
basas). The sample was serum taken right before 
the biopsy. The serum was collected and stored in 
-80°C until the examination was done. 
 
Proteinuria examination 
Proteinuria was the protein level in urine. 
Proteinuria examination was done using a dipstick 
(Multistix®) and urine protein/creatinine ratio 
calculation (UPCR). The sample used was urine 
taken immediately before the biopsy. The semi-
quantitative dipstick test results were: negative, 
1+, 2+, and 3+. The urine protein/creatinine ratio 
was determined by dividing the urine protein level 
(mg/dL) with urine creatinine (mg/dL). The results 
were reported in mg/mg. Dipstick method indica-
tes the severity of proteinuria; negative indicates 
no observable proteinuria and 3+ indicates severe 
proteinuria. UPCR result indicates kidney dama-
ge. More than 0.5 protein/creatinine ratio indicates 
abnormalities in kidneys [24, 25]. Quantitative 
urine protein examination was performed using 
the turbidimetry method (Roche/Hitachi Cobas C 
501). Urine creatinine examination was under-
taken using the enzymatic colorimetry method 
(Roche/Hitachi Cobas C 501). 
 
Data analysis 
Data analysis was performed using SPSS 16.0 
for Windows. Collected data would be tested by 
Kruskal-Wallis, Mann Whitney post hoc, and Spe-
arman correlation tests. The results were signifi-
cant if p < 0.05. 
 
Results and Discussion 
Subject characteristics 
Subject characteristics (Table 1) based on sex 
showed that the majority of patients were female, 
with a frequency of 94.3%. The majority of LN 
patients were aged 26 to 35 years old (45.3%). The 
most commonly found LN class was class III 
(37.7%). The location of immune complex depo-
sits was mostly in the mesangial, endothelial re-
gions, accounting for 35.8%. The results of prote- 
Table 1. Subject characteristics 
Variable n (53) 
Sex 
Male 3 (5.7%) 
Female 50 (94.3%) 
Age (years old) 
6-15  1 (1.9%) 
16-25  16 (30.2%) 
26-35  24 (45.3%) 
36-45  10 (18.9%) 
46-55  2 (3.8%) 
LN Class 
I 3 (5.7%) 
II 15 (28.3%) 
III 20 (37.7%) 
IV 7 (13.2%) 
IV and V 8 (15.1%) 
Location of immune complex deposit 
Mesangial 14 (26.4%) 
Mesangial, endothelial 19 (35.8%) 
Mesangial, endothelial, epithelial 5 (9.4%) 
Endothelial 10 (18.9%) 
Endothelial, epithelial 5 (9.4%) 
Proteinuria** 
Negative 17 (32.1%) 
1+ 7 (13.0%) 
2+ 14 (26.4%) 
3+ 15 (28.3%) 
Urine protein/creatinine ratio 
(mg/mg) 
3.03 (0.06 – 
98.16) * 
Anti-dsDNA level (IU/mL) 
93.0 (10.90 – 
916.60) * 
Note: * Median (minimum-maximum) 
** Proteinuria was measured using dipstick me-
thod: Negative result indicates no observable 
proteinuria while 3+ indicates severe protein-
uria, IU: International Unit, anti-dsDNA: anti-
double-stranded Deoxyribonucleic Acid 
 
inuria in LN patients examined with the dipstick 
test were mostly negative, accounting for 32.1%. 
The ratio of urine protein/creatinine in LN patients 
had a median of 3.03 mg/mg which indicates ab-
normality in their kidney [25]. The anti-dsDNA 
level in LN patients had a median of 93.0 IU/mL. 
The results showed that the majority of re-
search subjects were women and that the frequ-
ency of LN is higher in women than in men, with 
a ratio of 16.5 : 1. This frequency is much higher 
than that reported in the literature, which de-
scribed an LN ratio for women to men of 10:1 [4] 
because SLE is found in women more often than 
in men. This is believed to be because the major 
hormone which plays a role in SLE is estrogen 
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[26, 27]. In women, the metabolism of 17β-estra-
diol and estrone tends to produce 16-hydroxye-
strone and estriol, which are substances that can 
stimulate mitosis, thus contributing to the occur-
rence of inflammation. The levels of these com-
pounds may be higher in individuals with SLE  
than in healthy women [27]. 
The majority of patients in this study were 
within the reproductive age group (26 – 35 years). 
This is consistent with the statement that the SLE 
can occur in all age groups, with the most frequent 
incidence being for those of reproductive age, bet-
ween 15 and 40 years [28, 29]. Similar results 
were shown by Walker, who stated that SLE tends 
to occur in women of childbearing age [27]. 
When stratified by LN class, 37.7% of patients 
were LN Class III. This suggests that the LN prog-
nosis in these patients tends to be bad. Handono 
showed that 58% of LN patients with poor prog-
nosis have histopathological grade III, IV, or V 
[8]. Contreras et al. also showed a predominance 
of LN proliferation from 213 LN patients, ac-
counting for 30% of class III, 32% of class IV and 
18% of class V patients [6]. 
 
The Location of immune complex deposits and 
proteinuria 
This study found 5 groups of immune com-
plexes deposit locations, which were mesangial; 
mesangial, endothelial; mesangial, endothelial, 
epithelial; endothelial; and endothelial, epithelial. 
Comparisons of the severity of proteinuria were 
performed. Proteinuria was measured using a dye 
test strip and the protein: creatinine urine ratio. 
Kruskal-Wallis test analysis for proteinuria in 
LN patients with immune complex deposits in var-
ious locations showed a significant difference. The 
post hoc analysis Mann Whitney test showed a 
significant proteinuria difference in the location of 
immune complex deposits in the kidney (p < 0.05). 
There was an observable trend that the location of 
immune complex deposit was increasing the more 
severe the proteinuria was (Figure 1). The data 
suggested that proteinuria severity may have asso-
ciation with the location of immune complex de-
posit. Interestingly, immune deposit also observed 
in the negative proteinuria. 
The normality of the urine protein/creatinine 
ratio data was tested using the Kolmogorov-Smir-
nov test showed that the data did not have a normal 
distribution, even after data transformation; thus,  
Figure 1. Differences between Immune Complex De-
posit Location Group and Severity of Pro-
teinuria. The different letter indicated the 
significantly differences between goups 
based on Mann-Whitney test. Note: Ms= 
Mesangial; En= Endothelial; Ep=Epithelial; 
Proteinuria was measured using dipstick 
test; *p < 0.05 
 
Figure 2. Differences between Immune Complex De-
posit Location Group and Urine Protein/Cre-
atinine Ratio. The different letter indicated 
the significantly differences between groups 
based on Mann-Whitney test. Note: Ms = 
Mesangial; En = Endothelial; Ep =Epithe-
lial; UPCR = Urine Protein/creatinine ratio; 
Proteinuria was measured using dipstick 
test; *p<0.05 
 
the Kruskal-Wallis test was used to find out the 
differences in the urine protein/creatinine ratio in 
various location groups, with results that were sig- 
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nificantly different (p < 0.05). Interestingly, the 
data showed that higher protein/creatine ratio 
tends to have antibody complex deposit in epithe-
lial. It was observed that several immune complex 
deposit locations were associated with high pro-
tein/creatine ratio (Figure 2). 
Mann Whitney post hoc analysis in various 
groups showed a significant difference in urine 
protein/creatinine ratio for the mesangial group 
compared to the mesangial, endothelial, epithelial 
group and the endothelial, epithelial group, each 
with a p value of 0.005, for the mesangial, endo-
thelial group towards the mesangial, endothelial, 
epithelial group and the endothelial, epithelial 
group (both p = 0.021) and for the endothelial 
group towards the mesangial, endothelial, epithe-
lial group (p = 0.027) and the endothelial, epithe-
lial group (p = 0.020) (Figure 2). This indicated 
that the immune complex deposit location group 
that contained the same distribution as the epithe-
lium tends to represent heavy proteinuria. 
The assessment of severity of proteinuria with 
the dye strip test measurement analysis among im-
mune complex deposit locations tends to be less 
accurate than the protein: creatinine urine ratio. 
This is due to the proteinuria dye strip test is influ-
enced by physical activity [24, 30]. The use of the 
protein/creatinine ratio in urine has been recom-
mended by the ACR criteria for kidney, which cor-
relates well with 24-hour urine results. A protein: 
creatinine urine ratio > 0.5 can replace the pro-
teinuria dye strip test result of > 3+ [24, 25]. Iriane 
stated that the protein: creatinine urine ratio had a 
sensitivity (82.05%) and specificity (84.00%) 
which is good for LN [31]. 
SLE diseases include soluble immune com-
plex diseases; the clinical features are quite exten-
sive and involve many organs of the body. Inter-
actions between environmental, genetic and hor- 
monal factors in susceptible individuals generates 
an immune response that is abnormal, which with 
a loss of activity suppressor, causes the disruption 
of regulation and ineffective inhibition of CD4+ 
and CD8+ T-cells, and the decreased clearance of 
apoptotic cells and immune complexes. That pro-
cess can trigger a loss of self-tolerance and lead to 
the formation of autoantibodies deposited as im-
mune complexes in various body organs [3]. 
One serious manifestation of SLE is LN which 
is related to the production of nephritogenic auto-
antibodies. In general, the clinical feature of LN is 
a glomerular injury that occurs depending on the 
location of the immune complex deposits, as this 
determines the predominant glomerular cell type 
that is affected [32]. The immunopathology of the 
glomerulus begins from intraglomerular comple-
ment activation via the classical or alternative 
complement pathways. Immune complexes can be 
formed in many different compartments of the 
glomerulus, thereby determining the histopatho-
logical lesions. Different glomerular cell types pri-
marily undergo activation in each compartment. 
Histopathological features determine the classifi-
cation of glomerulonephritis. Immune complex 
deposits in mesangial and endothelial regions will 
activate mesangial and endothelial cells, causing 
mesangioproliferative glomerulopathy features 
[32], active urine sediment, and proteinuria, and is 
often accompanied by a decrease in kidney func-
tion. This is because the immune complex deposits 
were located proximal to the glomerular basement 
membrane, meaning that they also have access to 
vessels [9, 11]. Immune complex deposits in epi-
thelial cells primarily activate glomerular visceral 
epithelial cells known as Podosit and usually cause 
massive proteinuria. These cells are important as 
they act as the glomerular filtration barrier. Podo-
cytes loss causes progressive membranous neph- 
Table 2. Differences between Anti-dsDNA level and proteinuria 
Anti-dsDNA Level 
(IU/mL) 
Proteinuria (n=53) 
P value Negative 1+ 2+ 3+ 
N % n % N % N % 
< 60 10 18.9 2 3.8 4 7.5 4 7.5 
0.082 61 – 200 6 11.3 3 5.7 3 5.7 6 11.3 
> 200 1 1.9 2 3.8 7 13.2 5 9.4 
Total 17 32.1 7 13.2 14 26.4 15 28.3  
Note: Proteinuria was measured using dipstick method; Anti-dsDNA= Anti Double Stranded Deoxyribonucleic 
Acid; IU= International Unit. 
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ronpathy and ESRD, as a result of the slow regen-
eration process of podocytes when compared to 
other cells. Primary membranous nephropathy 
evolved from autoimmunity against PLA2R, 
while secondary nephropathy is derived from a 
systemic disease that manifests as LN kidney. 
Therefore, proteinuria is an important prognostic 
and predictive marker of glomerulopathy [32]. 
Some studies have reported cases of mesangial 
LN with heavy proteinuria and followed disease 
progression [10, 12, 33]. Immune deposits in the 
mesangial region usually cause early signs of renal 
involvement with mild symptoms, including in LN 
class II. However, the reported cases experienced 
heavy proteinuria and active urine sediment [10, 
33]. The pathogenesis is still unclear, but there is 
an idea that the immune complex deposits in the 
mesangial region would alter the glomerular per-
meability [10, 33]. Han et al. found that there is no 
correlation between immune complex deposits in 
the epithelium and proteinuria. There is no differ-
ence between patients with nephrotic and non-ne-
phrotic histology. Nephrotic syndrome is said to 
be well correlated with podocytopathy than depos-
its in the epithelial, mesangial or mesangial cells 
[12].   
The results of this study showed that there was 
no tendency towards severe proteinuria in the 
group where immune deposits are found in the ep-
ithelium, encompassing the mesangial, endothe-
lial, epithelial group and the endothelial, epithe-
lium group. 
 
Anti-dsDNA level with proteinuria 
The normality of anti-dsDNA level data was 
tested using the Kolmogorov-Smirnov test with p 
< 0.05. These data did not have a normal distribu-
tion, even though data transformation had been 
done; thus, the Kruskal-Wallis test was used to as-
sess the difference between different proteinuria 
severity level among different anti-dsDNA level 
groups, which showed no significant difference (p 
= 0.082) (Table 2). 
Difference tests among different urine protein 
/creatinine ratios with different levels of anti-
dsDNA level used the Kruskal-Wallis test and 
showed a significant difference. Mann Whitney 
post hoc analysis in several anti-dsDNA level 
groups showed a significant urine protein/creati-
nine difference, which was found in the groups 
with an anti-dsDNA level of < 60 and an anti- 
Figure 3.  The Differences of anti-dsDNA level to 
urine protein/creatinine ratio. The different 
letter indicated the significantly differences 
between groups based on Mann-Whitney 
test. Notes: UPCR = Urine Protein/creati-
nine ratio; Anti-dsDNA= Anti Double 
Stranded Deoxyribonucleic Acid; IU= Inter-
national Unit; *p < 0.05 
 
dsDNA level of > 200 IU/mL (p = 0.018), and the 
group with an anti-dsDNA level of 61 – 200 
IU/mL and an anti-dsDNA level of > 200 IU/mL 
(p = 0.014). Higher protein/creatine ratio level was 
mainly observed in the high anti-dsDNA level 
(Figure 3). This suggests that high levels of anti- 
dsDNA tend to cause heavy proteinuria. 
Results of Spearman correlation test found a 
significant association between anti-dsDNA level 
and the severity of proteinuria, measured by the 
dye strip check (p = 0.017) and protein: creatinine 
urine ratio (p = 0.040) with a correlation strength 
of 0.326 and 0.284, respectively. Anti-dsDNA an-
tibodies had a high sensitivity and specificity for 
the diagnosis of SLE and correlated with disease 
activity, especially for patients with nephritis [14]. 
Research conducted by Moroni et al., including 
107 LN patients, suggested that patients with high 
anti-dsDNA levels experienced significantly 
higher proteinuria [17]. 
A study by Linnik et al., of 487 patients with 
SLE and LN, stated that a history of anti-dsDNA 
levels that were higher than normal indicated 
changes in anti-dsDNA levels which were directly 
related to the risk of a renal flare-up [34]. Proper 
treatment to reduce anti-dsDNA levels in patients 
with LN may help to reduce the risk of kidney 
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damage and result in a better prognosis than in pa-
tients with higher and more stable levels of anti-
dsDNA [3]. The results of this study also showed 
a correlation between anti-dsDNA levels and the 
severity of proteinuria in LN patients, which is ex-
pected due to the administration of appropriate 
therapy that can reduce anti-dsDNA levels and 
proteinuria.  
This study split the anti-dsDNA level into 3 
groups: < 60 IU/mL (low positive), 61 to < 200 
IU/mL (positive) and > 200 IU/mL (high positive). 
The comparison between every anti-dsDNA level 
and every proteinuria severity level was perform-
ed using the dye strip test, giving results that were 
not significant, while the comparison of the pro-
tein : urine creatinine ratio was significant (p < 
0.05). This could be because the dye strip pro-
teinuria tests were less accurate and influenced by 
many factors such as those previously described; 
the sample amount was not significantly different 
between groups. 
The dsDNA antibody is specific for SLE [35] 
and plays a role in the pathogenesis of organ man-
ifestations, especially in the kidneys, where glo-
merulonephritis can occur [15]. Some factors that 
play a role in the pathogenicity of anti-dsDNA an-
tibodies are IgG isotype and the ability to improve 
the compliment, capacity, and affinity of dsDNA 
[34]. Proteinuria is one of the clinical manifesta-
tions that reflects disease activity in LN [36]. An-
imal studies by Fenton et al. stated that the produc-
tion of anti-dsDNA antibodies appears as immune 
complexes and excessive deposition in the kid-
neys, causing proteinuria [37]. Another study re-
ported that anti-dsDNA antibodies have also been 
found in the glomerulus of active LN patients, and 
differences in histopathological features were 
caused by differences in the location of the im-
mune complex deposits in the glomerulus [14]. 
Mechanisms can involve direct or indirect binding 
to the antigen, such as via extracellular matrix 
components and/or renal cells in the glomerulus, 
or cross-reactions with chromatin components, 
triggering cellular activation and cellular prolifer-
ation, resulting in inflammation and fibrosis [36]. 
 
Conclusion 
This study shows that the severity of pro-
teinuria in LN is determined by the location of im-
mune complex deposits in kidneys and anti-
dsDNA antibody levels. However, this study has 
limitations, as it uses only one type of immunoflu-
orescent staining antibody and the relatively low 
sample quantity. Another factor that may limit this 
study is the medical intervention to LN may sup-
press the flare (proteinuria and dsDNA level) in 
the system, as patient’s medical record is not in-
cluded. Therefore, it is expected that further re-
search can combine this with other antibodies, to 
provide better explanations about immune com-
plex deposits in LN. 
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